Table 4.
Summary of Gd+ lesion count at week 96 and stratified into quartiles by % ALC decline at week 96
| Without lymphopenia (always ALC ≥ LLN) n = 582a |
With lymphopenia (≥ 1 ALC < LLN) n = 452b |
Q1 (≥ 47% decline) n = 198 |
Q2 (30 to < 47% decline) n = 207 |
Q3 (12 to < 30% decline) n = 194 |
Q4 (< 12% decline) n = 202 |
All participants N = 1034c |
|
|---|---|---|---|---|---|---|---|
| No. of Gd+ lesions at week 96, mean (SD) | 0.6 (4.0) | 0.1 (0.8) | 0.1 (0.5) | 0.2 (1.6) | 0.6 (5.5) | 0.5 (2.0) | 0.3 (3.0) |
| Change from baseline at week 96, mean (SD) | − 0.4 (3.1) | − 1.1 (4.4) | − 0.9 (2.3) | − 0.7 (2.3) | − 0.6 (5.8) | − 0.7 (3.9) | − 0.7 (3.8) |
| No. of Gd+ lesions at week 96, n (%)d | |||||||
| 0 | 374/431 (86.8) | 370/383 (96.6) | 189/194 (97.4) | 195/203 (96.1) | 169/191 (88.5) | 171/201 (85.1) | 744/814 (91.4) |
| 1–4 lesions | 47/431 (10.9) | 12/383 (3.1) | 4/194 (2.1) | 7/203 (3.4) | 19/191 (9.9) | 24/201 (11.9) | 59/814 (7.2) |
| 5–8 lesions | 6/431 (1.4) | 0/383 | 1/194 (0.5) | 0/203 | 2/191 (1.0) | 3/201 (1.5) | 6/814 (0.7) |
| ≥ 9 lesions | 4/431 (0.9) | 1/383 (0.3) | 0/194 | 1/203 (0.5) | 1/191 (0.5) | 3/201 (1.5) | 5/814 (0.6) |
ALC absolute lymphocyte count, Gd+ gadolinium-enhancing, MRI magnetic resonance imaging, Q quartile
aOf 582 patients, 431 had baseline and week 96 Gd+ measurements
bOf 452 patients, 383 had baseline and week 96 Gd+ measurements
cOf 1034 patients, 814 had baseline and week 96 Gd+ measurements
dDenominator number of patients with baseline and week 96 Gd+ measurements